⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835263 | 1.00 | — | — | |
| SCHEMBL15769475 | 0.79 | — | — | |
| SCHEMBL2490205 | 0.75 | — | — | |
| SCHEMBL27820381 | 0.75 | — | — | |
| SCHEMBL12878591 | 0.75 | — | — | |
| SCHEMBL149516 | 0.72 | — | — | |
| SCHEMBL20267532 | 0.72 | KDM4E (0.43) | — | |
| Water SCHEMBL29599612 | 0.70 | — | — | |
| SCHEMBL23937701 | 0.70 | FTO (0.39) | — | |
| SCHEMBL11432532 | 0.70 | GLP1R (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | claimed |
| CN-110452355-B | Self-repairing rat-proof and termite-proof polyurethane, preparation method and application | 安徽建筑大学 | 2021-07-16 | — | — | CN | claimed |
| EP-3486234-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2021-06-02 | — | — | EP | claimed |
| CN-1615314-A | Phospholipid derivatives of nucleosides as antitumor agents | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2005-05-11 | — | — | CN | claimed |
| US-20050090659-A1 | Phospholepid derivatives of nucleosides as antitumaorl medicaments | GANYMED 256 VERMOEGENSVERWALTUNGS GMBH (DE) | 2005-04-28 | — | — | US | claimed |
| EP-1448579-A1 | PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AS ANTITUMORAL MEDICAMENTS | Heidelberg Pharma Holding GmbH (DE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003044035-A1 | PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AS ANTITUMORAL MEDICAMENTS | GANYMED 256 VERMÖGENSVERWALTUNGS GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| US-20260124314-A1 | ANTl-5T4 ANTIGEN BINDING DOMAINS, ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SALUBRIS BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260069620-A1 | IMMUNOTHERAPEUTIC PHOSPHOLIPIDS FOR CANCER TREATMENT | UNIVERSITY OF CINCINNATI (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260014253-A1 | CHECKPOINT REGULATOR ANTAGONISTS | GENSUN BIOPHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025245112-A1 | NEUREGULIN-1/ANTI-HER3 ANTIBODY FUSION PROTEIN FOR USE IN THE TREATMENT OF HEART FAILURE | SALUBRIS BIOTHERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250361306-A1 | ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS | GENSUN BIOPHARMA INC (US) | 2025-11-27 | — | — | US | disclosed |
| CN-100360564-C | Peptides and peptidomimetics having antiproliferative activity and/or enhancing the effect of nucleic acid damaging agents or treatments | CANBAS RES LAB LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| CN-101092455-A | Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments | CANBAS CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| CN-1642978-A | Peptides and peptidomimetics having antiproliferative activity and/or enhancing the effect of nucleic acid damaging agents or treatments | CANBAS RES LAB LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| CN-1615314-A | Phospholipid derivatives of nucleosides as antitumor agents | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2005-05-11 | — | — | CN | disclosed |
| US-20050090659-A1 | Phospholepid derivatives of nucleosides as antitumaorl medicaments | GANYMED 256 VERMOEGENSVERWALTUNGS GMBH (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1448579-A1 | PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AS ANTITUMORAL MEDICAMENTS | Heidelberg Pharma Holding GmbH (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003044035-A1 | PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES AS ANTITUMORAL MEDICAMENTS | GANYMED 256 VERMÖGENSVERWALTUNGS GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |